← All trials
NCT05772013
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2027
- First posted
- Mar 16, 2023
- Last posted
- Mar 16, 2023
- Enrollment
- 1311
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CambridgeLead sponsor
- University of CambridgeSponsor investigator
- Imperial College LondonCollaborator
- University of LiverpoolCollaborator
- University of LiverpoolCollaborator
- National Institute for Health Research, United KingdomCollaborator
- Newcastle UniversityCollaborator
- University of GlasgowCollaborator
- University of NottinghamCollaborator
- Imperial College LondonCollaborator
- Swansea UniversityCollaborator
- University of LondonCollaborator
- University of AberdeenCollaborator
- University of CambridgeCollaborator
- University of East AngliaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.